Skip to main content

Table 1 Baseline characteristics of the study population in training set (Huai’an, Jilin and Anhui) and in validation sets (Beijing)

From: FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients

Variables Huai’an (n = 252) Jilin (n = 297) Anhui (n = 408) Beijing (n = 332) p Value
Male sex, n 158 (63%) 168 (57%) 257 (63%) 203 (61%) 0.274
Median age (years) (IQR) 42 (32–49) 42 (33–50) 38 (29–48) 38 (30–47) 0.006
Median BMI (kg/m2) (IQR) 23.7 (22.5–25.1) 23.7 (21.6–26.0) 22.8 (20.4–25.4) 23.7 (21.0–26.1) 0.014
Median fasting LSM value (kPa) 10.4 (6.6–15.3) 7.9 (5.9–11.8) 5.7 (4.2–7.5) 7.8 (5.6–12.4) <  0.001
Median ALT (IU/L) (IQR) 42 (27–67) 39 (24–65) 49 (26–84.5) 46.2 (25.2–79.4) 0.046
Median AST (IU/L) (IQR) 35 (27–55) 32 (25–50) 34 (23–51) 33 (25–52) 0.108
Median GGT (IU/L) (IQR) 46 (24–98) 37 (21–79) 31.5 (21–73) 32 (19–60) <  0.001
Median total bilirubin (IU/L) (IQR) 15.8 (11.9–21.0) 14.4 (11.6–21.2) 17.7 (13.0–23.1) 14.3 (11.4–20) 0.654
Median platelet counts (109/L) (IQR) 165 (122–206) 179 (140–215) 161.5 (125–204) 186 (148–225) 0.148
Median APRI (IQR) 0.64 (0.41–1.35) 0.51 (0.33–0.84) 0.55 (0.34–0.92) 0.50 (0.30–0.76) <  0.001
Median FIB-4 (IQR) 1.61 (0.99–2.87) 1.22 (0.82–1.95) 1.17 (0.74–2.04) 1.07 (0.73–1.69) <  0.001
Ultrasound size of spleen (mm2) (IQR) 4410 (3866–5280) 3780 (2976–4710) 3468 (3120–3813) 3620 (2890–4560) <  0.001
Ultrasound diameter of spleen vein (mm) (IQR) 6 (5.2–7) 7 (6.7–8) 9 (8–10) 7 (6–8) <  0.001
Ultrasound diameter of portal vein (mm) (IQR) 11 (10–12) 12 (11–12) 11 (10–11) 11 (10–12) <  0.001
Ultrasound velocity of portal vein (m/s) (IQR) 0.16 (0.14–0.19) 0.11 (0.10–0.12) Not reported Not reported  
Median size of liver biopsy (mm) (IQR) 15 (12–16) 16 (12–19) 15 (12–20) 16 (13–18) <  0.001
Metavir fibrosis stage (F0/F1/F2/F3/F4) 21 (8.3%)/37 (14.7%)/46 (18.3%)/51 (20.2%)/97 (38.5%) 32 (10.8%)/77 (25.9%)/84 (28.3%)/44 (14.8%)/60 (20.2%) 10 (2.5%)/144 (35.3%)/129 (31.6%)/66 (16.2%)/59 (14.5%) 26 (7.9%)/127 (38.3%)/73 (22%)/32 (9.6%)/74 (22.3%) <  0.001
Metavir activity grade (A0/A1/A2/A3) 50 (19.8%)/106 (42.1%)/72 (28.6%)/24 (9.5%) 190 (64.0%)/54 (18.2%)/52 (17.5%)/1 (0.3%) 86 (21.1%)/254 (62.2%)/61 (15.0%)/7 (1.7%) 13 (3.9%)/154 (46.4%)/114 (34.3%)/51 (15.4%) <  0.001
  1. ALT alanine transaminase, APRI (AST)-to-platelet ratio index, AST aspartate transaminase, BMI body mass index, GGT gamma-glutamyl transpeptidase, LSM liver stiffness measurement